Survival curves of <i>EGFR</i>-mutated NSCLC patients treated with nivolumab. SatoMiyuki WatanabeSatoshi TanakaHiroshi NozakiKoichiro AritaMasashi TakahashiMiho ShojiSatoshi IchikawaKosuke KondoRie AokiNobumasa HayashiMasachika OhshimaYasuyoshi KoyaToshiyuki OhashiRiuko AjiokaYoichi KikuchiToshiaki 2019 <p>(A) Progression-free survival and (B) overall survival of patients treated with nivolumab.</p>